2. Search Result
Search Result
Results for "

Leishmania species

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Peptides

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162066
    DNDI-6174

    		Parasite Infection
    DNDI-6174 is an orally active Leishmania cytochrome b (Qi site of cytochrome bc1 complex/complex III) inhibitor. DNDI-6174 binds to the Qi site of Leishmania cytochrome b, inhibits cytochrome bc1 complex activity in the parasite's electron transport chain across promastigote and axenic amastigote stages. DNDI-6174 reduces parasite burden in rodent models, inhibits growth of various Leishmania species, drug-resistant clinical isolates, and Trypanosoma cruzi, with marginal activity against Trypanosoma brucei. DNDI-6174 can be used for the research of visceral leishmaniasis, cutaneous leishmaniasis .
    DNDI-6174
  • HY-134467
    Phylloflavan

    		Parasite NO Synthase Infection
    Phylloflavan is an antileishmanial (Antileishmanial) agent with an EC50 of 3.2 nM against intracellular amastigotes of Leishmania donovani. Phylloflavan is isolated from Phyllocldus plants. Phylloflavan induces moderate levels of NO release. Phylloflavan also inhibits the cytopathic effect of encephalomyocarditis virus on L929 fibroblasts (38 U/mL) .
    Phylloflavan
  • HY-B0956A
    Paromomycin

    Aminosidine

    		 Bacterial Parasite Endogenous Metabolite Infection
    Paromomycin (Aminosidine) is an orally active broad-spectrum aminoglycoside aminocyclitol. Paromomycin is produced by Streptomyces riomosus var. Paromomycinus. Paromomycin binding induces local conformational changes in the 16S rRNA A-site. Paromomycin exhibits inhibitory activity against C. parvum. Paromomycin can be used in research related to leishmaniasis, amoebiasis and cryptosporidiosis .
    Paromomycin
  • HY-156132
    DNDI-0690

    		Parasite Infection
    DNDI-0690 is a potent orally active analogue of DNDI-VL-2098, exhibiting potent activity against cutaneous leishmaniasis (CL). DNDI-0690 shows potent in vitro activity against CL-causing Leishmania species (EC50 = 0.17 μM against visceral leishmaniasis (VL), and < 5 μM against CL-causing species). DNDI-0690 exerts effects in a mouse model of L. major CL. DNDI-0690 can be used for CL research .
    DNDI-0690
  • HY-146166
    PT4

    		Parasite Reactive Oxygen Species (ROS) Infection Inflammation/Immunology
    PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity .
    PT4
  • HY-175364
    Antiparasitic agent-27

    		Parasite Reactive Oxygen Species (ROS) Infection
    Antiparasitic agent-27 (Compound 2) is a potent antiparasitic agent targeting Leishmania infantum (IC50=3.1 μM). Antiparasitic agent-27 induces G0/G1 cell cycle arrest and reactive oxygen species (ROS) generation to trigger programmed cell death. Antiparasitic agent-27 is promising for research of visceral leishmaniasis (VL) .
    Antiparasitic agent-27
  • HY-183262
    Antileishmanial agent-40

    		Parasite Reactive Oxygen Species (ROS) Infection
    Antileishmanial agent-40 is an orally active and selective antileishmanial agent. Antileishmanial agent-40 elevates intracellular reactive oxygen species (ROS) levels in Leishmania donovani promastigotes. Antileishmanial agent-40 induces cell cycle arrest at the sub-G0/G1 phase in Leishmania donovani promastigotes, indicative of programmed-like parasite death. Antileishmanial agent-40 can be used for the research of leishmaniasis .
    Antileishmanial agent-40
  • HY-183290
    Antileishmanial agent-41

    		Parasite Reactive Oxygen Species (ROS) Infection
    Antileishmanial agent-41 (Compound 20k) is a selective Antileishmanial agent with a IC50 of 1.51 μg/mL against Leishmania donovani. Antileishmanial agent-41 increases ROS levels. Antileishmanial agent-41 can be used for the research of leishmaniasis .
    Antileishmanial agent-41
  • HY-183621
    Antileishmanial agent-43

    		Parasite Reactive Oxygen Species (ROS) Autophagy Infection
    Antileishmanial agent-43 is a 3,4,5‑trisubstituted isoxazole with selective antileishmanial activity. Antileishmanial agent-43 shows IC50 values of 12.7 μM against Leishmania amazonensis promastigotes and 0.96 μM against intracellular amastigotes. Antileishmanial agent-43 induces ROS elevation, oxidative stress and mitochondrial dysfunction, resulting in lipid peroxidation, mitochondrial depolarization and ATP imbalance. Antileishmanial agent-43 causes cell shrinkage, phosphatidylserine externalization, plasma membrane permeabilization, and promotes autophagy. Antileishmanial agent-43 can be used for the research of leishmaniasis .
    Antileishmanial agent-43

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: